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Background: Little is known about the long-term outcomes after drug-eluting stent (DES) implantation in saphenous vein graft (SVG) lesions. The 
first randomized trial comparing DES with bare metal stents (BMS) in SVGs reported higher mortality in the DES group at 32 months.
Methods: The SOS trial (NCT00247208) randomized 80 patients with 112 lesions in 88 SVGs to a BMS or paclitaxel-eluting stent (PES). We have 
previously reported improved short-term angiographic and clinical outcomes with PES in these patients. We now report longer-term outcomes after 
enrollment in the SOS trial (median follow-up 29 months).
Results: Mean age was 67 ± 9 years and all patients were men. The indications for angiography and stenting included acute coronary syndrome in 
60%, and stable angina in 31%. The mean SVG age was 12 ± 6 years. The baseline characteristics of the patients in the 2 study groups were similar. 
Diabetes was present in 44%. The territory supplied by the target SVGs was the left anterior descending artery in 28%, the circumflex in 38%, and the 
right coronary artery in 34%. An embolic protection device was used in 54% of the lesions. Procedural success was achieved in 77 patients (96%). 
The long-term outcomes after stenting are shown in the Table.
Table: long-term outcomes in the SOS trial 
Clinical event
BMS
(N=39)
PES
(N=41)
Hazard ratio (95% CI) P Value
Death, n (%) 4 (10%) 7 (17%) 1.79 (0.52, 6.11) 0.36
Cardiac death, n (%) 4 (10%) 1 (3%) 0.27 (0.03, 2.40) 0.24
Myocardial infarction, n (%) 18 (46%) 6 (15%) 0.27 (0.11, 0.69) 0.006
Target lesion revascularization, n (%) 16 (41%) 2 (5%) 0.10 (0.02, 0.44) 0.002
Target vessel revascularization, n (%) 18 (46%) 7 (17%) 0.34 (0.14, 0.80) 0.01
Any revascularization, n (%) 23 (59%) 8 (20%) 0.27 (0.12, 0.60) 0.001
Death or myocardial infarction, n (%) 20 (51%) 12 (29%) 0.49 (0.24, 0.99) 0.05
Target vessel failure, n (%) 26 (67%) 10 (24%) 0.28 (0.14, 0.59) 0.001
Device-oriented composite endpoint, n (%) 26 (67%) 6 (15%) 0.16 (0.06, 0.39) <0.001
Overall major adverse cardiac events (patient-oriented 
composite endpoint), n (%)
28 (72%) 17 (41%) 0.68 (0.37, 1.25) 0.22
Definite or probable stent thrombosis by ARC criteria, n (%) 6 (15%) 1 (2%) 0.16 (0.02, 1.29 0.09
Conclusions: Major cardiac adverse events are frequent after SVG lesion stenting. PES are associated with significantly better clinical outcomes 
than BMS in SVG lesions.
